Arcus Biosciences

US · RCUS #2467 by market cap Listed 2018

24.52 +0.24 +0.99%

Live - 5344 symbols - heartbeat 482s ago · 2026-10-07 19:54

After-hours 24.52 0.00%

Market cap: 3.12B
P/E (TTM): -6.22
P/B: 6.73
EPS: -3.29
Div yield: 0.00%
52W pos: 57%

Reader sentiment Are you bullish or bearish on RCUS?

Anonymous reader poll. Unscientific, not investment advice.

About Arcus Biosciences

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Founded: 2015
CEO: Dr. Terry Rosen, PhD
Employees: 601
Headquarters: Hayward, California, United States of America
Fiscal year end: 12-31
Website: arcusbio.com

Company profile

Exchange: US
Symbol: RCUS
Market-cap rank: #2467
Listing date: 2018-03-15
Market cap: 3.12B
Float cap: 2.22B
Shares out: 127.33M
Float shares: 90.53M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.